KINIKSA PHARMACEUTICALS LTD's ticker is KNSA and the CUSIP is G5269C101. A total of 108 filers reported holding KINIKSA PHARMACEUTICALS LTD in Q3 2022. The put-call ratio across all filers is 0.49 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $642,613 | -20.3% | 37,013 | -35.4% | 0.00% | 0.0% |
| Q2 2023 | $806,167 | +70.3% | 57,268 | +30.3% | 0.00% | +50.0% |
| Q1 2023 | $473,516 | -29.0% | 43,962 | -1.2% | 0.00% | +100.0% |
| Q4 2022 | $667,072 | +35.0% | 44,503 | +15.8% | 0.00% | -50.0% |
| Q3 2022 | $494,000 | +7.9% | 38,440 | -18.7% | 0.00% | 0.0% |
| Q2 2022 | $458,000 | -2.6% | 47,296 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $470,000 | +84.3% | 47,296 | +118.1% | 0.00% | +100.0% |
| Q4 2021 | $255,000 | +9.0% | 21,684 | +5.8% | 0.00% | 0.0% |
| Q3 2021 | $234,000 | +53.9% | 20,501 | +88.3% | 0.00% | 0.0% |
| Q2 2021 | $152,000 | -24.8% | 10,890 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $202,000 | +12.2% | 10,890 | -33.2% | 0.00% | 0.0% |
| Q4 2019 | $180,000 | +56.5% | 16,299 | +20.8% | 0.00% | 0.0% |
| Q3 2019 | $115,000 | -18.4% | 13,491 | +29.7% | 0.00% | 0.0% |
| Q2 2019 | $141,000 | – | 10,399 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Spearhead Capital Advisors, LLC | 202,580 | $2,601,000 | 2.82% |
| Lion Point Capital, LP | 480,000 | $5,140,000 | 1.13% |
| HHLR ADVISORS, LTD. | 2,920,023 | $37,493,000 | 0.99% |
| TANG CAPITAL MANAGEMENT LLC | 600,000 | $7,704,000 | 0.94% |
| Rubric Capital Management LP | 1,446,107 | $18,568,000 | 0.94% |
| AlphaCentric Advisors LLC | 43,000 | $552,000 | 0.57% |
| RICE HALL JAMES & ASSOCIATES, LLC | 749,933 | $9,629,000 | 0.56% |
| Parkman Healthcare Partners LLC | 126,192 | $1,620,000 | 0.46% |
| Birchview Capital, LP | 30,000 | $385,000 | 0.27% |
| Baker Brothers Advisors | 2,799,577 | $35,947,000 | 0.24% |